Gland Pharma share news, announcements and annual reports
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Gland Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2020 · Issue price ₹1,500
Last close ₹3,074.50up ₹25.50 (0.84%)BSE ₹3,074.85
Share price at the NSE close on 29 Oct 2026. Previous close ₹3,049.00.
29 Oct: open ₹3,060.00, high ₹3,111.20, low ₹3,011.00
52-week range of traded prices to 29 Oct 2026
₹1,573.60Low, 16 Mar 2026₹3,171.00High, 7 Oct 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹50,733 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 44.94
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.90
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.65%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,86,09368.5% delivered
Gland Pharma board and management
32 filed, newest first.
Oct 2026
1 Oct · Management
Aug 2026
Jul 2026
20 Jul · Management
Jun 2026
15 Jun · Management
May 2026
14 May · Management
Apr 2026
Mar 2026
Feb 2026
Jan 2026
29 Jan · Management
Aug 2025
28 Aug · Management
28 Aug · Management
Mar 2025
10 Mar · Management
Jan 2025
15 Jan · Management
Dec 2024
3 Dec · Management
Nov 2024
4 Nov · Management
Oct 2024
18 Oct · Management
Sep 2024
10 Sep · Management
Aug 2024
30 Aug · Management
12 Aug · Management
Jun 2024
7 Jun · Management
May 2024
31 May · Management
Apr 2024
29 Apr · Management
Mar 2024
25 Mar · Management
Nov 2023
20 Nov · Management
Oct 2023
17 Oct · Management
Sep 2023
4 Sep · Management
Aug 2023
31 Aug · Management
7 Aug · Management
Mar 2022